Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-s
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
04:15pm, Wednesday, 29'th Oct 2025
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is gen
Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?
11:01am, Friday, 10'th Oct 2025
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
12:36pm, Thursday, 18'th Sep 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
08:30am, Thursday, 18'th Sep 2025
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Wave Life Sciences price target lowered to $18 from $21 at Wells Fargo
06:36am, Thursday, 04'th Sep 2025
Wells Fargo analyst Tiago Fauth lowered the firm's price target on Wave Life Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported AATD data update for 200 a
Wave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference Transcript
03:10pm, Wednesday, 03'rd Sep 2025
Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Chris
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?
01:28pm, Wednesday, 03'rd Sep 2025
Wave Life Sciences Ltd. WVE stock is trading lower on Wednesday after the company shared data from the ongoing Phase 1b/2a RestorAATion-2 Trial of WVE-006 in alpha-1 antitrypsin deficiency.
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
07:30am, Wednesday, 03'rd Sep 2025
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)
Wave (WVE) Q2 Revenue Drops 56%
03:10am, Thursday, 31'st Jul 2025
Wave (WVE) Q2 Revenue Drops 56%
Wave Life Sciences Ltd. (WVE) Q2 2025 Earnings Call Transcript
09:38pm, Wednesday, 30'th Jul 2025
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2025 Earnings Conference Call July 30, 2025 8:30 AM ET Company Participants Erik Ingelsson - Chief Scientific Officer Kate Rausch - Head of Investor Relations
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
10:01am, Wednesday, 30'th Jul 2025
Wave Life Sciences (WVE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.25 per share a year ago.
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
07:30am, Wednesday, 30'th Jul 2025
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patien
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
08:30am, Wednesday, 23'rd Jul 2025
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months
05:42pm, Monday, 07'th Jul 2025
Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington's, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying oppor
